Astra's Price of Immortality
Astra's purchase of Merck's share of the company's joint venture may represent an emotional overreaction to the Swedish company's earlier strategic timidity. Few mid-sized companies in the 1980s (Glaxo being a notable exception) were aggressive enough to use their drugs as currency for entering the US market and building a significant presence. Merck was able to take advantage of several of them--including Astra. Now with a warchest gleaned from DuPont's and Astra's repurchase of their joint ventures, Merck, facing its biggest challenges in nearly two decades, can fund a larger marketing effort, more research, or afford the kinds of expensive licensing deals it's heretofore resisted.
You may also be interested in...
Developed by Japan’s national research institute, the supercomputer has been tasked with characterizing the SARS-CoV-2 virus, identifying therapeutic molecules, modeling infection spread and socio-economic impact.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Wound care company MiMedx has raised $150m in private equity and debt financing from EW Healthcare Partners and Hayfin Capital Management. The funds will be used to scale commercialization of the company’s amniotic tissue products.